Search

Your search keyword '"Lillo-Le Louet, A."' showing total 44 results
Start Over Author "Lillo-Le Louet, A." Publication Year Range Last 10 years
44 results on '"Lillo-Le Louet, A."'

2. Bleeding risk of intramuscular injection of COVID‐19 vaccines in adult patients with therapeutic anticoagulation

Author

Gendron, Nicolas, Khider, Lina, Le Beller, Christine, Espinasse, Benjamin, Auditeau, Claire, Amara, Wafa, Perrin, Germain, Lebeaux, David, Gaiffe, Anais, Combret, Sandrine, Bertin, Blandine, Lillo‐Le Louet, Agnès, Mirault, Tristan, Smadja, David M., Sanchez, Olivier, Tromeur, Cécile, Planquette, Benjamin, and Couturaud, Francis

Published
2022
Full Text
View/download PDF

4. Heparin‐induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation

Author

Tardy‐Poncet, Brigitte, de Maistre, Emmanuel, Pouplard, Claire, Presles, Emilie, Alhenc‐Gelas, Martine, Lasne, Dominique, Horellou, Marie‐Hélène, Mouton, Christine, Serre‐Sapin, Anne, Bauters, Anne, Nguyen, Philippe, Mullier, François, Perrin, Julien, Le Gal, Grégoire, Morange, Pierre‐Emmanuel, Grunebaum, Lélia, Lillo‐Le Louet, Agnès, Elalamy, Ismail, Gruel, Yves, Greinacher, Andreas, Lecompte, Thomas, and Tardy, Bernard

Published
2021
Full Text
View/download PDF

6. Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes

Author

T-V. Bui, C. Prot-Bertoye, H. Ayari, S. Baron, J-P. Bertocchio, C. Bureau, P. Davis, A. Blanchard, P. Houillier, D. Prie, A. Lillo-Le Louet, and M. Courbebaisse

Subjects
inulin (PubChem CID: 16219508), safety, hypersensitivity, pharmacovigilance, sinistrin, Therapeutics. Pharmacology, RM1-950
Abstract

Introduction: Inulin and its analog sinistrin are fructose polymers used in the food and pharmaceutical industries. In 2018, The French National Agency for the Safety of Medicines and Health Products (ANSM) decided to withdraw products containing sinistrin and inulin due to several reports of serious hypersensitivity reactions, including a fatal outcome.Objective: To assess the safety of inulin and sinistrin use in France.Methods: We searched multiple sources to identify adverse reactions (ARs) to inulin or sinistrin: first, classical pharmacovigilance databases including the French Pharmacovigilance (FPVD) and the WHO Database (VigiBase); second, data from a clinical trial, MultiGFR; third, data regarding current use in an hospital. All potential ARs to inulin or sinistrin were analyzed with a focus on hypersensitivity reactions and relationships to batches of sinistrin.Results: From 1991 to 2018, 134 ARs to inulin or sinistrin were registered in the FPVD or VigiBase. Sixty-three cases (47%) were classified as serious, and 129 cases (96%) were hypersensitivity reactions. We found an association between a batch of sinistrin and the occurrence of hypersensitivity reactions. During the MultiGFR clinical trial, 7 patients (7/163 participants) had an Adverse reaction; of these, 4 were hypersensitivity reactions including one case of grade 4 anaphylactic shock. In the hospital, no ARs were observed. In the literature, ARs to inulin and sinistrin are very rarely reported and mostly benign.Conclusion: Most ARs to inulin and sinistrin are hypersensitivity reactions that appear to be associated with sinistrin batches.

Published
2021
Full Text
View/download PDF

7. Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series

Author

Julie Carré, Hippolyte Guérineau, Christine Le Beller, Laëtitia Mauge, Benoit Huynh, Roya Nili, Benjamin Planquette, Sylvain Clauser, David M. Smadja, Dominique Helley, Agnès Lillo-Le Louet, Nicolas Gendron, and Leyla Calmette

Subjects
heparin-induced thrombocytopenia, direct oral anticoagulant, thrombosis, platelets, apixaban, rivaroxaban, Medicine (General), R5-920
Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a prothrombotic life-threatening disorder caused by an adverse reaction to heparin exposure. In this context, it is imperative to stop heparin immediately and to replace it by a non-heparin anticoagulant therapy. Despite their advantages, the use of direct oral anticoagulants (DOACs) is only emerging for HIT treatment, and their use remains rare.Objective: To improve our knowledge on the emerging role of DOACs as treatment of HIT and give an overview of our local practices in this context.Patients/Methods: This is a multi-centric retrospective case series of HIT patients referred to our Parisian pharmacovigilance network and treated with DOACs.Results: We report the cases of seven patients from four healthcare centers, diagnosed with HIT (4T score ≥ 4, positive anti-PF4/heparin immunoassay and positive serotonin-release assay) and treated with DOACs. After a few days on substitutive parenteral treatment (n = 6) or directly at HIT diagnosis (n = 1), these patients were treated with either rivaroxaban (n = 6) or apixaban (n = 1) during acute HIT phase. Mean time to platelet count recovery after heparin discontinuation was 3.3 days (range 3–5). No patient experienced major or clinically relevant non-major bleeding or thrombosis that could be related to DOAC treatment during follow-up.Conclusions: Our cases studies are consistent with recent guidelines credit to the potential and safe use of DOAC during acute HIT in clinically stable patients.

Published
2021
Full Text
View/download PDF

9. Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study

Author

Clement, Olivier, Dewachter, Pascale, Mouton-Faivre, Claudie, Nevoret, Camille, Guilloux, Laurence, Bloch Morot, Evelyne, Katsahian, Sandrine, Laroche, Dominique, Audebert, Martine, Benabes-Jezraoui, Béatrice, Benoit, Yves, Beot, Sylvie, Berard, Frédéric, Berthezene, Yves, Bertrand, Philippe, Bouffard, Juliette, Bourrain, Jean-Luc, Boyer, Bruno, Carette, Marie-France, Caron-Poitreau, Christine, Cavestri, Béatrice, Cercueil, Jean Pierre, Charpin, Denis-André, Collet, Evelyne, Crombe-Ternamian, Arielle, Dalmas, Jacques, Decoux, Eric, Defrance, Marie-France, Delaval, Yvonne, Demoly, Pascal, Depriester, Claude, Depriester, Pascale, Didier, Alain, Drouet, Martine, Dupas, Benoît, Dupre-Goetchebeur, Dominique, Dzviga, Charles, Fabre, Christine, Ferretti, Gilbert, Fourre-Jullian, Corinne, Girardin, Pascal, Giron, Jacques, Gouitaa, Marion, Grenier, Nicolas, Guenard Bilbault, Lydie, Guez, Stéphane, Gunera-Saad, Nathalie, Heautot, Jean-François, Herbin, Dominique, Hoarau, Cyrille, Jacquot, Claude, Julien, Christian, Laborie, Laurent, Lambert, Claude, Larroche, Pascal, Leclerc, Xavier, Lemaitre, Laurent, Leynadier, Francisque, Lillo-Le-Louet, Agnès, Louvel, Jean-Pierre, Louvier, Nathalie, Lucas, Marie-Madeleine, Meites, Geneviève, Mennesson, Nicolas, Metge, Liliane, Meunier, Yannick, Monnier-Cholley, Laurence, Musacchio, Mariano, Nicolie, Brigitte, Occelli, Gisèle, Oesterle, Hélène, Paisant-Thouveny, Francine, Panuel, Michel, Railhac, Nadine, Rety-Jacob, Frédérique, Rochefort-Morel, Cécile, Roy, Catherine, Sarlieve, Philippe, Sesay, Musa, Sgro, Catherine, Taourel, Patrice, Terrier, Patrick, Theissen, Odile, Topenot, Ingrid, Valfrey, Jocelyne, Veillon, Francis, Vergnaud, Marie-Claude, Veyret, Charles, Vincent, Denis, Wallaert, Benoit, Wessel, François, and Zins, Marc

Published
2018
Full Text
View/download PDF

10. Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study

Author

Olivier Clement, Pascale Dewachter, Claudie Mouton-Faivre, Camille Nevoret, Laurence Guilloux, Evelyne Bloch Morot, Sandrine Katsahian, Dominique Laroche, Martine Audebert, Béatrice Benabes-Jezraoui, Yves Benoit, Sylvie Beot, Frédéric Berard, Yves Berthezene, Philippe Bertrand, Juliette Bouffard, Jean-Luc Bourrain, Bruno Boyer, Marie-France Carette, Christine Caron-Poitreau, Béatrice Cavestri, Jean Pierre Cercueil, Denis-André Charpin, Evelyne Collet, Arielle Crombe-Ternamian, Jacques Dalmas, Eric Decoux, Marie-France Defrance, Yvonne Delaval, Pascal Demoly, Claude Depriester, Pascale Depriester, Alain Didier, Martine Drouet, Benoît Dupas, Dominique Dupre-Goetchebeur, Charles Dzviga, Christine Fabre, Gilbert Ferretti, Corinne Fourre-Jullian, Pascal Girardin, Jacques Giron, Marion Gouitaa, Nicolas Grenier, Lydie Guenard Bilbault, Stéphane Guez, Nathalie Gunera-Saad, Jean-François Heautot, Dominique Herbin, Cyrille Hoarau, Claude Jacquot, Christian Julien, Laurent Laborie, Claude Lambert, Pascal Larroche, Xavier Leclerc, Laurent Lemaitre, Francisque Leynadier, Agnès Lillo-Le-Louet, Jean-Pierre Louvel, Nathalie Louvier, Marie-Madeleine Lucas, Geneviève Meites, Nicolas Mennesson, Liliane Metge, Yannick Meunier, Laurence Monnier-Cholley, Mariano Musacchio, Brigitte Nicolie, Gisèle Occelli, Hélène Oesterle, Francine Paisant-Thouveny, Michel Panuel, Nadine Railhac, Frédérique Rety-Jacob, Cécile Rochefort-Morel, Catherine Roy, Philippe Sarlieve, Musa Sesay, Catherine Sgro, Patrice Taourel, Patrick Terrier, Odile Theissen, Ingrid Topenot, Jocelyne Valfrey, Francis Veillon, Marie-Claude Vergnaud, Charles Veyret, Denis Vincent, Benoit Wallaert, François Wessel, and Marc Zins

Subjects
Medicine (General), R5-920
Abstract

Background: Iodinated and gadolinium-based contrast media (ICM; GBCM) induce immediate hypersensitivity (IH) reactions. Differentiating allergic from non-allergic IH is crucial; allergy contraindicates the culprit agent for life. We studied frequency of allergic IH among ICM or GBCM reactors. Methods: Patients were recruited in 31 hospitals between 2005 and 2009. Clinical symptoms, plasma histamine and tryptase concentrations and skin tests were recorded. Allergic IH was diagnosed by intradermal tests (IDT) with the culprit CM diluted 1:10, “potentially allergic” IH by positive IDT with pure CM, and non-allergic IH by negative IDT. Findings: Among 245 skin-tested patients (ICM = 209; GBCM = 36), allergic IH to ICM was identified in 41 (19.6%) and to GBCM in 10 (27.8%). Skin cross-reactivity was observed in 11 patients with ICM (26.8%) and 5 with GBCM (50%). Allergy frequency increased with clinical severity and histamine and tryptase concentrations (p 50% of life-threatening ones. GBCM and ICM triggered comparable IH reactions in frequency and severity. Cross-reactivity was frequent, especially for GBCM. We propose considering skin testing with pure contrast agent, as it is more sensitive than the usual 1:10 dilution criteria.

Published
2018
Full Text
View/download PDF

12. Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series.

Author

Ammar, Helmi, Le Beller, Christine, Bouccara, Didier, Malinvaud, David, Jouffroy, Romain, and Lillo‐Le Louet, Agnès

Subjects
BENIGN paroxysmal positional vertigo, COVID-19 vaccines, COVID-19 pandemic, BALANCE disorders, MESSENGER RNA
Abstract

Background: There are few publications regarding manifestations of vestibular disorders (VDs) following BNT162b2 mRNA COVID‐19 vaccination. Purpose: We describe cases of VD potentially related to BNT162b2 vaccination and calculate its reporting rate, in order to enlarge knowledge about this adverse effect. Methods: A retrospective analysis of cases of VD following BNT162b2 vaccination reported to the pharmacovigilance centre of Georges‐Pompidou European Hospital (France), in 2021 was performed. In order to identify these cases from the pharmacovigilance database containing all our registered cases, we used the Standardised MedDRA Query (SMQ) 'vestibular disorders'. Then we analysed cases with vestibular symptoms, based on the association of typical manifestations. The reporting rate was calculated based on the number of VD cases and the number of vaccinated patients. Results: Among 6608 cases reported to our centre related to COVID‐19 vaccines during 2021, 34 VDs associated with BNT162b2 administration were included. They were mainly reported in females (79%), 62% occurred after the first dose and 32% were serious. Symptoms had completely resolved in 13 cases (38%). Vertigo was the most common symptom followed by balance disorders. Three patients received second dose without reappearance of VD. The final diagnosis was reported in 10 patients (six cases of vestibular neuritis, two cases of central VD, two cases of benign paroxysmal positional vertigo). The regional reporting rate was 26 [95% CI: 17–34] cases of VD per 1 million persons vaccinated. Conclusion: Although the relationship between vaccination and VD cannot be established, clinicians should be aware of this rare adverse effect. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Fluoroquinolone use preceding medium-size artery dissection: A case series

Author

Wang, L., primary, Oehmichen, B., additional, Pariente, B., additional, Mohamedi, N., additional, Cheng, C., additional, Détriché, G., additional, Galloula, A., additional, Khider, L., additional, Lillo Le Louet, A., additional, Messas, E., additional, Amar, L., additional, Goudot, G., additional, and Mirault, T., additional

Published
2023
Full Text
View/download PDF

17. Bleeding risk of intramuscular injection of COVID-19 vaccines in adult patients with therapeutic anticoagulation

Author

Nicolas Gendron, Lina Khider, Christine Le Beller, Benjamin Espinasse, Claire Auditeau, Wafa Amara, Germain Perrin, David Lebeaux, Anais Gaiffe, Sandrine Combret, Blandine Bertin, Agnès Lillo‐Le Louet, Tristan Mirault, David M. Smadja, Olivier Sanchez, Cécile Tromeur, Benjamin Planquette, Francis Couturaud, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Paris Cité (UPCité), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Health data- and model- driven Knowledge Acquisition (HeKA), Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), and Hospices Civils de Lyon (HCL)

Subjects
Adult, COVID-19 Vaccines, SARS-CoV-2, Anticoagulants, COVID-19, Humans, Hematology, Injections, Intramuscular, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2022

18. Toxic optic neuropathy due to voriconazole: possible potentiation by reduction of CYP2C19 activity

Author

C, Orssaud, R, Guillemain, and A, Lillo Le Louet

Subjects
Cytochrome P-450 CYP2C19, Male, Antifungal Agents, Adolescent, Toxic Optic Neuropathy, Antitubercular Agents, Aspergillosis, Cytochrome P-450 CYP2C19 Inhibitors, Humans, Drug Synergism, Voriconazole, Tuberculosis, Pulmonary, Ethambutol
Abstract

Voriconazole is an antifungal treatment with central neurotoxicity. Modifications of the electroretinogram can explain some of its visual complications: visual hallucination, blurred vision, altered visual perception or photophobia. However, reports from the literature or the French pharmacovigilance centers evoked toxic optic neuropathy due to voriconazole. The aim of this report is to analyze the role of voriconazole in the occurrence of toxic optic neuropathy or the role of the combination of voriconazole with other neurotoxic drugs.We report the case of a 15-year-old young boy treated with voriconazole and ethambutol for a severe lung infection due to aspergillosis and mycobacterium tuberculosis in the mucoviscidosis and pulmonary transplantation who developed a toxic optic neuropathy. A review of the literature on the role of ethambutol on the activity of CYP2C19 and its relationship with the serum concentration of voriconazole was conducted.In our patients, visual acuity recovered after discontinuation of voriconazole. Other cases of toxic optic neuropathy due to voriconazole were reported in pharmaco-vigilance databases, often in association with ethambutol.Ethambutol can reduce the activity of CYP2C19 leading to an increase of voriconazole concentration. Thus, it potentiates its risk of adverse event. Such mechanism leading to this neuro ophthalmological adverse effect would have an important clinical involvement. It would require a stricter monitoring and screening of patients treated by combination of neurotoxic molecules and VRZ to detect an adverse event.

Published
2022

19. Direct Oral Anticoagulants as Successful Treatment of Heparin-Induced Thrombocytopenia: A Parisian Retrospective Case Series

Author

Carré, Julie, Guérineau, Hippolyte, Le Beller, Christine, Mauge, Laëtitia, Huynh, Benoit, Nili, Roya, Planquette, Benjamin, Clauser, Sylvain, Smadja, David M., Helley, Dominique, Lillo-Le Louet, Agnès, Gendron, Nicolas, and Calmette, Leyla

Subjects
platelets, apixaban, Medicine, direct oral anticoagulant, General Medicine, heparin-induced thrombocytopenia, rivaroxaban, thrombosis, Original Research
Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a prothrombotic life-threatening disorder caused by an adverse reaction to heparin exposure. In this context, it is imperative to stop heparin immediately and to replace it by a non-heparin anticoagulant therapy. Despite their advantages, the use of direct oral anticoagulants (DOACs) is only emerging for HIT treatment, and their use remains rare. Objective: To improve our knowledge on the emerging role of DOACs as treatment of HIT and give an overview of our local practices in this context. Patients/Methods: This is a multi-centric retrospective case series of HIT patients referred to our Parisian pharmacovigilance network and treated with DOACs. Results: We report the cases of seven patients from four healthcare centers, diagnosed with HIT (4T score ≥ 4, positive anti-PF4/heparin immunoassay and positive serotonin-release assay) and treated with DOACs. After a few days on substitutive parenteral treatment (n = 6) or directly at HIT diagnosis (n = 1), these patients were treated with either rivaroxaban (n = 6) or apixaban (n = 1) during acute HIT phase. Mean time to platelet count recovery after heparin discontinuation was 3.3 days (range 3–5). No patient experienced major or clinically relevant non-major bleeding or thrombosis that could be related to DOAC treatment during follow-up. Conclusions: Our cases studies are consistent with recent guidelines credit to the potential and safe use of DOAC during acute HIT in clinically stable patients.

Published
2021
Full Text
View/download PDF

21. Can We Reduce Frame Rate to 15 Images per Second in Pediatric Videofluoroscopic Swallow Studies?

Author

Clement, Olivier, Dewachter, Pascale, Mouton-Faivre, Claudie, Nevoret, Camille, Guilloux, Laurence, Bloch Morot, Evelyne, Katsahian, Sandrine, Laroche, Dominique, Audebert, Martine, Benabes-Jezraoui, Béatrice, Benoit, Yves, Beot, Sylvie, Berard, Frédéric, Berthezene, Yves, Bertrand, Philippe, Bouffard, Juliette, Bourrain, Jean-Luc, Boyer, Bruno, Carette, Marie-France, Caron-Poitreau, Christine, Cavestri, Béatrice, Cercueil, Jean Pierre, Charpin, Denis-André, Collet, Evelyne, Crombe-Ternamian, Arielle, Dalmas, Jacques, Decoux, Eric, Defrance, Marie-France, Delaval, Yvonne, Demoly, Pascal, Depriester, Claude, Depriester, Pascale, Didier, Alain, Drouet, Martine, Dupas, Benoît, Dupre-Goetchebeur, Dominique, Dzviga, Charles, Fabre, Christine, Ferretti, Gilbert, Fourre-Jullian, Corinne, Girardin, Pascal, Giron, Jacques, Gouitaa, Marion, Grenier, Nicolas, Guenard Bilbault, Lydie, Guez, Stéphane, Gunera-Saad, Nathalie, Heautot, Jean-François, Herbin, Dominique, Hoarau, Cyrille, Jacquot, Claude, Julien, Christian, Laborie, Laurent, Lambert, Claude, Larroche, Pascal, Leclerc, Xavier, Lemaitre, Laurent, Leynadier, Francisque, Lillo-Le-Louet, Agnès, Louvel, Jean-Pierre, Louvier, Nathalie, Lucas, Marie-Madeleine, Meites, Geneviève, Mennesson, Nicolas, Metge, Liliane, Meunier, Yannick, Monnier-Cholley, Laurence, Musacchio, Mariano, Nicolie, Brigitte, Occelli, Gisèle, Oesterle, Hélène, Paisant-Thouveny, Francine, Panuel, Michel, Railhac, Nadine, Rety-Jacob, Frédérique, Rochefort-Morel, Cécile, Roy, Catherine, Sarlieve, Philippe, Sesay, Musa, Sgro, Catherine, Taourel, Patrice, Terrier, Patrick, Theissen, Odile, Topenot, Ingrid, Valfrey, Jocelyne, Veillon, Francis, Vergnaud, Marie-Claude, Veyret, Charles, Vincent, Denis, Wallaert, Benoit, Wessel, François, Zins, Marc, Layly, Julie, Marmouset, Franck, Chassagnon, Guillaume, Sirinelli, Dominique, Cottier, Jean-Philippe, Morel, Baptiste, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pathophysiology of the Vigilance States (SLEEP), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Groupe Hospitalier Universitaire Paris Seine-Saint-Denis (GHUPSSD), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Biomnis Laboratory, Service de Médecine Interne [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Centre de référence des syndromes drépanocytaires majeurs, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Amiens-Picardie, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département d'allergie et d'immunologie clinique [CHU Lyon Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Hôpital de la Croix-Rousse [CHU - HCL], Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Université Paris Cité (UPCité), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])

Subjects
Male, medicine.medical_specialty, Adolescent, Pediatrics, Sensitivity and Specificity, [SHS]Humanities and Social Sciences, 030507 speech-language pathology & audiology, 03 medical and health sciences, Speech and Hearing, 0302 clinical medicine, Swallowing, Image Processing, Computer-Assisted, medicine, Humans, Child, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, business.industry, Cineradiography, Gastroenterology, Reproducibility of Results, Frame rate, University hospital, Dysphagia, Deglutition, Pediatric Radiology, Otorhinolaryngology, Child, Preschool, Radiological weapon, Female, Radiology, medicine.symptom, Deglutition Disorders, 0305 other medical science, business, 030217 neurology & neurosurgery, Pediatric population
Abstract

Videofluoroscopic Swallow studies (VFSS) are useful radiological examinations to explore swallowing disorders but which require ionizing radiation. The aim of our study was to evaluate the comparability of pediatric VFSS at 15 frames per second (fps) with 30 fps. Fifty-five loops including 190 swallowings of VFSS at 30 fps performed on 32 consecutive pediatric patients in a University Hospital Center were retrospectively modified by a software to delete one image out of two to obtain secondary loops with a frame rate of 15 fps. An otorhinolaryngologist-phonatrician and a radiologist reviewed all swallowings blindly and randomly using the penetration and aspiration scale (PAS). In case of discordance, they concluded a consensual interpretation. Fifteen girls and seventeen boys were included. The median age was 4 years and 8 months (range = 4 months-16 yr.). 144 swallowings were normal. Swallowing disorder was confirmed in 46 swallowings, (23 supraglottic penetrations and 23 aspirations). Considering each swallowing at 15 fps, sensitivity and specificity were, respectively, 93% (CI 0.82-0.98) and 98% (CI 0.94-0.99). The Cohen'Kappa coefficient between each interpretation at 15 and 30 fps was "almost perfect" (κ = 0.95; CI 0.88-0.99). Considering each loop, conclusion was identical. Reducing frame rate at 15 fps during pediatric VFSS seemed to be acceptable with comparable diagnostic performances without clinical impact compared to 30 fps, while being an efficient way to reduce the ionizing radiation exposition in children. We would suggest reconsidering the possibility of using VFSS with a 15 fps in a pediatric population.

Published
2019

23. Heparin-induced thrombocytopenia: construction of a pre-test diagnostic score derived from the analysis of a prospective multinational database, with internal validation.

Author

UCL - (MGD) Laboratoire de biologie clinique, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Tardy-Poncet, Brigitte, de Maistre, Emmanuel, Pouplard, Claire, Presles, Emilie, Alhenc-Gelas, Martine, Lasne, Dominique, Horellou, Marie-Hélène, Mouton, Christine, Serre-Sapin, Anne, Bauters, Anne, Nguyen, Philippe, Mullier, François, Perrin, Julien, Le Gal, Grégoire, Morange, Pierre-Emmanuel, Grunebaum, Lélia, Lillo-Le Louet, Agnès, Elalamy, Ismail, Gruel, Yves, Greinacher, Andreas, Lecompte, Thomas, Tardy, Bernard, GFHT-HIT study group, UCL - (MGD) Laboratoire de biologie clinique, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Tardy-Poncet, Brigitte, de Maistre, Emmanuel, Pouplard, Claire, Presles, Emilie, Alhenc-Gelas, Martine, Lasne, Dominique, Horellou, Marie-Hélène, Mouton, Christine, Serre-Sapin, Anne, Bauters, Anne, Nguyen, Philippe, Mullier, François, Perrin, Julien, Le Gal, Grégoire, Morange, Pierre-Emmanuel, Grunebaum, Lélia, Lillo-Le Louet, Agnès, Elalamy, Ismail, Gruel, Yves, Greinacher, Andreas, Lecompte, Thomas, Tardy, Bernard, and GFHT-HIT study group

Abstract

Diagnosis of heparin-induced thrombocytopenia (HIT) requires pre-test probability assessment and dedicated laboratory assays. To develop a pre-test score for HIT. Observational; analysis of prospectively collected data of hospitalized patients suspected with HIT (ClinicalTrials.gov NCT00748839). Thirty-one tertiary hospitals in France, Switzerland, and Belgium. Patients tested for HIT antibodies (2,280 evaluable), randomly allocated to derivation and validation cohorts. Independent adjudicators diagnosed HIT based on the prospectively collected data and Serotonin Release Assay results. HIT was diagnosed in 234 (14.7%) and 99 (14.5%) patients in the two cohorts. Eight features were associated with HIT (in brackets, points assigned for score calculation of the score): unfractionated heparin (1); therapeutic-dose heparin (1); cardiopulmonary bypass (cardiac surgery) (2); major trauma (3); 5- to 21-day interval from anticoagulation initiation to suspicion of HIT (4); ≥ 40% decrease in platelet count over ≤ six days (3); thrombotic event, arterial (3) or venous (3). The C-statistic was 0.79 [95% CI, 0.76-0.82]. In the validation cohort, the area under the receiver operating characteristic curve was 0.77 [95% CI, 0.74-0.80]. Three groups of scores were defined; HIT prevalence reached almost 30% in the high-probability group. The performance of the score may depend on settings and practices. The objective, easy-to-collect, clinical features of HIT we evidenced were incorporated into a pre-test score, which may guide clinical decisions regarding diagnostic testing and anticoagulation.

Published
2021

24. Prise de fluoroquinolones précédant une dissection d’artère viscérale

Author

Louise Wang, Boris Oemichen, Grégoire Détriché, Andréanne Durivage, Alexandre Galloula, Nassim Mohamedi, Lina Khider, Charles Cheng, Agnès Lillo Le Louet, Emmanuel Messas, Laurence Amar, Guillaume Goudot, and Tristan Mirault

Subjects
Cardiology and Cardiovascular Medicine
Published
2022

26. Intramuscular Vaccination in Adults with Therapeutic Anticoagulation in the Era of COVID-19 Vaccines Outbreak: A Practical Review

Author

Perrin, Germain, additional, Beller, Christine Le, additional, Darnige, Luc, additional, Khider, Lina, additional, Smadja, David M., additional, Lillo-Le Louet, Agnès, additional, Planquette, Benjamin, additional, Lebeaux, David, additional, Sanchez, Olivier, additional, Sabatier, Brigitte, additional, Mirault, Tristan, additional, and Gendron, Nicolas, additional

Published
2021
Full Text
View/download PDF

27. Clin Pharmacol Ther

Author

Mareva Faure, Yola Moride, Bernard Bégaud, Agnès Lillo-Le-Louet, Anne-Marie Castilloux, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, medicine.medical_specialty, MEDLINE, Comorbidity, 030226 pharmacology & pharmacy, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Risk Factors, Internal medicine, Secondary Prevention, Medicine, Humans, Pharmacology (medical), Aged, Proportional Hazards Models, Pharmacology, Aged, 80 and over, PharmacoEpi-Drugs, business.industry, Proportional hazards model, Hazard ratio, Age Factors, Anticoagulants, Cardiovascular Agents, Pharmacoepidemiology, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Clinical trial, Stroke, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Guideline Adherence, business, Platelet Aggregation Inhibitors, Cohort study
Abstract

Using claims databases of a public healthcare program (Quebec) for the years 2010–2013, we conducted a cohort study of patients with acute ischemic stroke (AIS) to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs. In the month after discharge, 44.3% of the patients did not receive the recommended treatment and > 20% did not have any treatment. Untreated patients were younger, had less comorbidities, and a more severe AIS. Anticoagulants and antiplatelets were associated with a reduced risk of death or recurrence (hazard ratio (HR) 0.27; 95% confidence interval (CI) 0.20–0.36 and HR 0.25; 95% CI 0.16–0.38, respectively) compared with the untreated group. Effect size was similar for the other treatments. Findings confirm treatment benefits shown in clinical trials and emphasize the importance of AIS secondary prevention.

Published
2020

28. Diagnosis of Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical Score Based on Objective Features Identified by a Multivariate Analysis of a Multinational Prospective Study

Author

Brigitte Tardy-Poncet, Emmanuel de Maistre, Claire Pouplard, Emilie Presles, Martine Alhenc-Gelas, Dominique Lasne, Marie-Hélène Horellou, Christine Mouton, Anne Serre-Sapin, Anne Bauters, Philippe Nguyen, François Mullier, Julien Perrin, Grégoire Le Gal, Pierre Morange, Lélia Grunebaum, Agnès Lillo-Le Louet, Ismail Elalamy, Yves Gruel, Andreas Greinacher, Thomas Lecompte, Bernard Tardy, and GFHT-HIT Study Group

Subjects
medicine.medical_specialty, Multivariate analysis, business.industry, Major trauma, medicine.disease, Intensive care unit, law.invention, Informed consent, law, Internal medicine, Heparin-induced thrombocytopenia, Good clinical practice, Medicine, Observational study, business, Prospective cohort study
Abstract

Background: Diagnosis of heparin-induced thrombocytopenia (HIT) is based on a composite of clinical likelihood and laboratory testing. We aimed to develop a diagnostic score derived from multivariate analysis of clinical features, including platelet count changes, prospectively recorded in patients with suspected HIT. Methods: This multinational observational study (ClinicalTrials.gov no. NCT00748839) included 2280 adult patients with suspected HIT: 1597 (derivation cohort) formed the basis for developing the scoring system, subsequently validated in 683 additional randomly selected patients (validation cohort). HIT was diagnosed by two independent adjudicators based on clinical features, local laboratory data, and the results of a centrally performed serotonin release assay (SRA). Findings: Overall, 56.7% of the patients were treated in an intensive care unit of whom 57.4% received unfractionated heparin; thromboembolism occurred in 12.3%. In the derivation and validation cohorts, 234 (14.7%) and 99 (14.5%) patients, respectively, were diagnosed with HIT. Eight features were positively associated with HIT diagnosis in a multivariate model (in brackets the value assigned for score calculation): unfractionated heparin use (1); therapeutic-dose heparin use (1); cardiac surgery with cardiopulmonary bypass (2); major trauma (3); 5- to 21-day interval from anticoagulant treatment initiation to suspicion of HIT (4); ≥ 40% decrease in platelet count over ≤ 6 days during the last 10 days of anticoagulation exposure (3); thrombotic event, either arterial (3) or venous (3). The C statistic of the model was 0.791 [0.76; 0.82] (p-value 0.70, Hosmer-Lemeshow test). In the validation cohort, the area under the ROC curve was 0.77 [95% CI 0.74-0.80], and HIT prevalence was 2.6% for a score ≤2; 6% for a score of 3–8; and 28.8% for a score >8: Interpretation: This study distinguishes validated clinical features of HIT, permitting improved estimation of its likelihood. Trial Registration: (ClinicalTrials.gov no. NCT00748839) Funding Statement: Programme Hospitalier de Recherche Clinique (French Health Ministry), Sanofi, LFB, Organon SA. Declaration of Interests: Dr. Mullier reports personal fees from Aspen, personal fees from Stago, grants from Werfen, outside the submitted work; Dr. Gruel reports personal fees from Sanofi, personal fees from LFB, other from Stago, personal fees from Aspen, outside the submitted work; . All other authors declare no conflict of interests. Ethics Approval Statement: The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki, Good Clinical Practice, and relevant French, Swiss and Belgian legal and regulatory requirements regarding data protection. The protocol was approved by French, Swiss and Belgian independent ethics committees. All patients received written information about the study, emphasizing their right to refuse participation or to withdraw at any time. As no experimental interventions were induced from the protocol, no written informed consent was required for inclusion.

Published
2019

29. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis

Author

Sylvie Lariven, Lucie Le Meur, Yazdan Yazdanpanah, L. Massias, Agnès Lillo-Le-Louet, Emilie Desselas, Gilles Peytavin, Romain Sonneville, Christine Bonnal, Minh Patrick Lê, Diane Descamps, Claire Tantet, and Julie Giraud

Subjects
Male, 0301 basic medicine, Microbiology (medical), Antifungal Agents, Darunavir+Ritonavir, Anti-HIV Agents, Itraconazole, 030106 microbiology, HIV Infections, Histoplasmosis, Plasma, 03 medical and health sciences, 0302 clinical medicine, Hiv infected, Humans, Medicine, Drug Interactions, Pharmacology (medical), 030212 general & internal medicine, Adverse effect, Darunavir, Pharmacology, Ritonavir, business.industry, Mental Disorders, Middle Aged, medicine.disease, Virology, Infectious Diseases, Plasma chemistry, business, medicine.drug
Published
2017

30. Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study

Author

Dominique Herbin, Jacques Dalmas, Frédéric Berard, Jean-Luc Bourrain, Laurence Monnier-Cholley, Laurent Lemaitre, P. Girardin, Agnès Lillo-Le-Louet, Christian Julien, Lydie Guenard Bilbault, François Wessel, Jean Pierre Cercueil, Charles Veyret, Yvonne Delaval, Hélène Oesterle, Liliane Metge, Sylvie Beot, Béatrice Cavestri, Laurent Laborie, Philippe Bertrand, Arielle Crombe-Ternamian, Evelyne Collet, Evelyne Bloch Morot, Nicolas Mennesson, Claude Jacquot, Francis Veillon, Ingrid Topenot, Christine Caron-Poitreau, Brigitte Nicolie, Olivier Clément, Marie-Madeleine Lucas, Martine Audebert, Christine Fabre, Musa Sesay, Jacques Giron, Frédérique Rety-Jacob, Geneviève Meites, Francisque Leynadier, Xavier Leclerc, Pascal Larroche, Catherine Sgro, Claude Depriester, Alain Didier, Laurence Guilloux, Francine Paisant-Thouveny, Gisèle Occelli, Philippe Sarlieve, Sandrine Katsahian, Juliette Bouffard, Stéphane Guez, D. Laroche, Jean-Pierre Louvel, Corinne Fourre-Jullian, Claude Lambert, Yves Berthezene, Denis Vincent, Nicolas Grenier, Charles Dzviga, Cécile Rochefort-Morel, Yannick Meunier, Marie-France Defrance, Odile Theissen, Pascal Demoly, Michel Panuel, Eric Decoux, Cyrille Hoarau, Béatrice Benabes-Jezraoui, Marie-France Carette, Mariano Musacchio, Jean-François Heautot, Benoît Dupas, Benoit Wallaert, Denis-André Charpin, Gilbert Ferretti, Camille Nevoret, Pascale Dewachter, Marion Gouitaa, Patrice Taourel, Pascale Depriester, Yves Benoit, Bruno Boyer, Jocelyne Valfrey, Nadine Railhac, Martine Drouet, Nathalie Louvier, Claudie Mouton-Faivre, Catherine Roy, Marie-Claude Vergnaud, Nathalie Gunera-Saad, Marc Zins, Patrick Terrier, Dominique Dupre-Goetchebeur, Service de Radiologie [CHU HEGP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Biomnis Laboratory, Service de Médecine Interne [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Centre de référence des syndromes drépanocytaires majeurs, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Amiens-Picardie, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Service d'immunologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse [CHU - HCL], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Grenoble, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Nord [CHU - APHM], Service de Dermatologie (CHU de Dijon), CH Martigues, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier Saint-Joseph [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], Université de Montpellier (UM), Service de pneumologie [Toulouse], CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Service de radiologie [Saint-Etienne], CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service central de radiologie et d'imagerie médicale, CHU Grenoble-Hôpital Michallon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Purpan [Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], Centre Hospitalier Public du Cotentin (CHPC), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Clinique de réanimation médicale, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, CHU Saint-Etienne, Département de radiologie [Brest] (DR - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Services de neuroradiologie [Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Claude Huriez [Lille], CHU Lille, Service de Radiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Hôpital de Rangueil, Service de réanimation médicale [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Radiologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Hôpital pasteur [Colmar], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Strasbourg, Laboratoire de Pharmacologie-Toxicologie [CHU de Dijon], Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], Service de radiologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service de Médecine générale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de pneumologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe hospitalier Paris Saint-Joseph - Hôpital, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Service de radiologie et imagerie médicale [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre Hospitalier Public du Cotentin [Cherbourg-Octeville] (CHPC), Service de Néphrologie et d’Immunologie Clinique [CHRU Tours], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Hôpital Jean Minjoz, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Herrada, Anthony, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Saint-Etienne-Université Jean Monnet - Saint-Étienne (UJM), Institut des Neurosciences de Montpellier (INM), CH Centre Hospitalier Public du Cotentin (CHPC), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre de référence des syndromes drépanocytaires majeurs-Hôpital Européen Georges Pompidou [APHP] (HEGP), Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours

Subjects
medicine.medical_specialty, Allergy, Tryptase, Gastroenterology, Culprit, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Clinical severity, lcsh:R5-920, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, biology, business.industry, General Medicine, medicine.disease, 3. Good health, 030228 respiratory system, chemistry, biology.protein, Intradermal test, Plasma histamine, lcsh:Medicine (General), business, Histamine, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Paper
Abstract

International audience; Background:Iodinated and gadolinium-based contrast media (ICM; GBCM) induce immediate hypersensitivity (IH) reactions. Differentiating allergic from non-allergic IH is crucial; allergy contraindicates the culprit agent for life. We studied frequency of allergic IH among ICM or GBCM reactors.Methods:Patients were recruited in 31 hospitals between 2005 and 2009. Clinical symptoms, plasma histamine and tryptase concentrations and skin tests were recorded. Allergic IH was diagnosed by intradermal tests (IDT) with the culprit CM diluted 1:10, "potentially allergic" IH by positive IDT with pure CM, and non-allergic IH by negative IDT.Findings:Among 245 skin-tested patients (ICM = 209; GBCM = 36), allergic IH to ICM was identified in 41 (19.6%) and to GBCM in 10 (27.8%). Skin cross-reactivity was observed in 11 patients with ICM (26.8%) and 5 with GBCM (50%). Allergy frequency increased with clinical severity and histamine and tryptase concentrations (p 50% of life-threatening ones. GBCM and ICM triggered comparable IH reactions in frequency and severity. Cross-reactivity was frequent, especially for GBCM. We propose considering skin testing with pure contrast agent, as it is more sensitive than the usual 1:10 dilution criteria.

Published
2018

34. Pharmacology and social media: Potentials and biases of web forums for drug mention analysis—case study of France.

Author

Audeh, Bissan, Calvier, François-Elie, Bellet, Florelle, Beyens, Marie-Noëlle, Pariente, Antoine, Lillo-Le Louet, Agnès, and Bousquet, Cedric

Subjects
DRUG therapy, DATABASE management, DATABASES, DRUG utilization, DRUG side effects, MACHINE learning, MARKETING, MEDICAL prescriptions, ORAL contraceptives, PHARMACOLOGY, RESEARCH funding, STATISTICS, WORLD Wide Web, SOCIAL media
Abstract

The aim of this study is to analyze drug mentions in web forums to evaluate the utility of this data source for drug post-marketing studies. We automatically annotated over 60 million posts extracted from 21 French web forums. Drug mentions detected in this corpus were matched to drug names in a French drug database (Theriaque®). Our analysis showed that a high proportion of the most frequent drug mentions in the selected web forums correspond to drugs that are usually prescribed to young women, such as combined oral contraceptives. The most mentioned drugs in our corpus correlated weakly to the most prescribed drugs in France but seemed to be influenced by events widely reported in traditional media. In this article, we conclude that web forums have high potential for post-marketing drug-related studies, such as pharmacovigilance, and observation of drug utilization. However, the bias related to forum selection and the corresponding population representativeness should always be taken into account. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Secondary Stroke Prevention: A Population‐Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence.

Author

Faure, Mareva, Castilloux, Anne‐Marie, Lillo‐Le‐Louet, Agnès, Bégaud, Bernard, and Moride, Yola

Subjects
COHORT analysis, APIXABAN, ANTICOAGULANTS, STROKE, CARDIOVASCULAR agents, COMORBIDITY, CONFIDENCE intervals
Abstract

Using claims databases of a public healthcare program (Quebec) for the years 2010–2013, we conducted a cohort study of patients with acute ischemic stroke (AIS) to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs. In the month after discharge, 44.3% of the patients did not receive the recommended treatment and > 20% did not have any treatment. Untreated patients were younger, had less comorbidities, and a more severe AIS. Anticoagulants and antiplatelets were associated with a reduced risk of death or recurrence (hazard ratio (HR) 0.27; 95% confidence interval (CI) 0.20–0.36 and HR 0.25; 95% CI 0.16–0.38, respectively) compared with the untreated group. Effect size was similar for the other treatments. Findings confirm treatment benefits shown in clinical trials and emphasize the importance of AIS secondary prevention. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis

Author

Le Meur, Lucie, primary, Tantet, Claire, additional, Lê, Minh Patrick, additional, Desselas, Emilie, additional, Bonnal, Christine, additional, Lillo-Le-Louet, Agnès, additional, Sonneville, Romain, additional, Massias, Laurent, additional, Giraud, Julie, additional, Descamps, Diane, additional, Yazdanpanah, Yazdan, additional, Lariven, Sylvie, additional, and Peytavin, Gilles, additional

Published
2017
Full Text
View/download PDF

39. Detection of Drug–Drug Interactions Inducing Acute Kidney Injury by Electronic Health Records Mining

Author

Yannick Girardeau, Antoine Neuraz, Paul Avillach, Lillo-Le Louet Agnes, Christine Le Beller, P. Degoulet, Claire Trivin, Pierre Durieux, Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biomedical informatics and public health department, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Department of nephrology, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Department of pharmacovigilance, Center for biomedical informatics, Harvard Medical School [Boston] (HMS), Children's hospital informatics program, Boston Children's Hospital, Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), APHP, Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Harvard Medical School [Boston] ( HMS ), Children's Hospital of Boston, Administateur, HAL Sorbonne Université, and Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE)

Subjects
Adult, Male, [ SDV.MHEP.UN ] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Drug, medicine.medical_specialty, media_common.quotation_subject, Toxicology, Sensitivity and Specificity, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, chemistry.chemical_compound, Clarithromycin, Internal medicine, Data Mining, Electronic Health Records, Humans, Medicine, Drug Interactions, Pharmacology (medical), Rifle, Adverse effect, Intensive care medicine, Aged, Retrospective Studies, media_common, Aged, 80 and over, Pharmacology, Creatinine, business.industry, Acute kidney injury, Odds ratio, Acute Kidney Injury, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Confidence interval, 3. Good health, [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, [ SDV.SP ] Life Sciences [q-bio]/Pharmaceutical sciences, chemistry, Female, business, Algorithms, medicine.drug
Abstract

International audience; Background and Objective : While risk of acute kidney injury (AKI) is a well documented adverse effect of some drugs, few studies have assessed the relationship between drug–drug interactions (DDIs) and AKI. Our objective was to develop an algorithm capable of detecting potential signals on this relationship by retrospectively mining data from electronic health records.Material and methods : Data were extracted from the clinical data warehouse (CDW) of the Hôpital Européen Georges Pompidou (HEGP). AKI was defined as the first level of the RIFLE criteria, that is, an increase ≥50 % of creatinine basis. Algorithm accuracy was tested on 20 single drugs, 10 nephrotoxic and 10 non-nephrotoxic. We then tested 45 pairs of non-nephrotoxic drugs, among the most prescribed at our hospital and representing distinct pharmacological classes for DDIs.Results : Sensitivity and specificity were 50 % [95 % confidence interval (CI) 23.66–76.34] and 90 % (95 % CI 59.58–98.21), respectively, for single drugs. Our algorithm confirmed a previously identified signal concerning clarithromycin and calcium-channel blockers (unadjusted odds ratio (ORu) 2.92; 95 % CI 1.11–7.69, p = 0.04). Among the 45 drug pairs investigated, we identified a signal concerning 55 patients in association with bromazepam and hydroxyzine (ORu 1.66; 95 % CI 1.23–2.23). This signal was not confirmed after a chart review. Even so, AKI and co-prescription were confirmed for 96 % (95 % CI 88–99) and 88 % (95 % CI 76–94) of these patients, respectively.Conclusion : Data mining techniques on CDW can foster the detection of adverse drug reactions when drugs are used alone or in combination.

Published
2015

42. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.

Author

Meur, Lucie Le, Tantet, Claire, Lê, Minh Patrick, Desselas, Emilie, Bonnal, Christine, Lillo-Le-Louet, Agnès, Sonneville, Romain, Massias, Laurent, Giraud, Julie, Descamps, Diane, Le Meur, Lucie, Yazdanpanah, Yazdan, Lariven, Sylvie, and Peytavin, Gilles

Subjects
ANTIRETROVIRAL agents, MARAVIROC (Drug), DARUNAVIR, RITONAVIR, ABACAVIR-lamivudine (Drug), AMPHOTERICIN B, ANTIBIOTICS, BIOPSY, CEREBROSPINAL fluid, COMBINATION drug therapy, COGNITION disorders, SEIZURES (Medicine), DIARRHEA, DRUG interactions, GLUCANS, HEADACHE, HISTOPLASMOSIS, HIV infections, HIV-positive persons, KIDNEY diseases, MEDICAL prescriptions, NEURORADIOLOGY, PARAPLEGIA, POLYMERASE chain reaction, POLYSACCHARIDES, RNA, SPASMS, MYELITIS, STEROIDS, WEIGHT loss, DETOXIFICATION (Substance abuse treatment), SENSORY disorders, VIRAL meningitis, DIAGNOSIS, ITRACONAZOLE, THERAPEUTICS
Published
2018
Full Text
View/download PDF

43. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.

Author

Le Meur, Lucie, Tantet, Claire, Le, Minh Patrick, Desselas, Emilie, Bonnal, Christine, Lillo-Le-Louet, Agnès, Sonneville, Romain, Massias, Laurent, Giraud, Julie, Descamps, Diane, Yazdanpanah, Yazdan, Lariven, Sylvie, and Peytavin, Gilles

Subjects
NEUROPSYCHIATRY, ITRACONAZOLE, HISTOPLASMOSIS
Published
2018
Full Text
View/download PDF

44. Toxic optic neuropathy due to voriconazole: possible potentiation by reduction of CYP2C19 activity.

Author

Orssaud C, Guillemain R, and Lillo Le Louet A

Subjects
Adolescent, Cytochrome P-450 CYP2C19, Drug Synergism, Humans, Male, Antifungal Agents adverse effects, Antitubercular Agents therapeutic use, Aspergillosis drug therapy, Cytochrome P-450 CYP2C19 Inhibitors therapeutic use, Ethambutol therapeutic use, Toxic Optic Neuropathy, Tuberculosis, Pulmonary drug therapy, Voriconazole adverse effects
Abstract

Objective: Voriconazole is an antifungal treatment with central neurotoxicity. Modifications of the electroretinogram can explain some of its visual complications: visual hallucination, blurred vision, altered visual perception or photophobia. However, reports from the literature or the French pharmacovigilance centers evoked toxic optic neuropathy due to voriconazole. The aim of this report is to analyze the role of voriconazole in the occurrence of toxic optic neuropathy or the role of the combination of voriconazole with other neurotoxic drugs., Patients and Methods: We report the case of a 15-year-old young boy treated with voriconazole and ethambutol for a severe lung infection due to aspergillosis and mycobacterium tuberculosis in the mucoviscidosis and pulmonary transplantation who developed a toxic optic neuropathy. A review of the literature on the role of ethambutol on the activity of CYP2C19 and its relationship with the serum concentration of voriconazole was conducted., Results: In our patients, visual acuity recovered after discontinuation of voriconazole. Other cases of toxic optic neuropathy due to voriconazole were reported in pharmaco-vigilance databases, often in association with ethambutol., Conclusions: Ethambutol can reduce the activity of CYP2C19 leading to an increase of voriconazole concentration. Thus, it potentiates its risk of adverse event. Such mechanism leading to this neuro ophthalmological adverse effect would have an important clinical involvement. It would require a stricter monitoring and screening of patients treated by combination of neurotoxic molecules and VRZ to detect an adverse event.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results